Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

T Denda, D Sakai, T Hamaguchi, N Sugimoto… - Cancer …, 2019 - Wiley Online Library
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer

T Denda, D Sakai, T Hamaguchi… - Cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5-fluorouracil/levofolinate …

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer

T Denda, D Sakai, T Hamaguchi… - Cancer …, 2019 - kyushu-u.elsevierpure.com
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5-fluorouracil/levofolinate …

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.

T Denda, D Sakai, T Hamaguchi, N Sugimoto… - Cancer …, 2019 - europepmc.org
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

T Denda, D Sakai, T Hamaguchi, N Sugimoto, T Ura… - Cancer Science, 2019 - cir.nii.ac.jp
抄録< jats: p> Aflibercept targets vascular endothelial growth factor. The present study
involved assessing the efficacy, safety and pharmacokinetics of aflibercept plus 5 …

[HTML][HTML] Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

T Denda, D Sakai, T Hamaguchi, N Sugimoto… - Cancer …, 2019 - ncbi.nlm.nih.gov
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

T Denda, D Sakai, T Hamaguchi, N Sugimoto… - Cancer …, 2019 - search.proquest.com
Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …

[PDF][PDF] Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

森脇俊和, モリワキトシカズ - Cancer science, 2019 - tsukuba.repo.nii.ac.jp
Colorectal cancer is the third most commonly occurring cancer worldwide and the second
leading cause of cancer-related deaths. 1 In Japan, it is the most commonly occurring …

[引用][C] Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

森脇 - Cancer Science, 2019 - cir.nii.ac.jp
Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients
with metastatic colorectal cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …